JP2013224953A5 - - Google Patents

Download PDF

Info

Publication number
JP2013224953A5
JP2013224953A5 JP2013133614A JP2013133614A JP2013224953A5 JP 2013224953 A5 JP2013224953 A5 JP 2013224953A5 JP 2013133614 A JP2013133614 A JP 2013133614A JP 2013133614 A JP2013133614 A JP 2013133614A JP 2013224953 A5 JP2013224953 A5 JP 2013224953A5
Authority
JP
Japan
Prior art keywords
cancer
use according
cells
nucleoside
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013133614A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013224953A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2013224953A publication Critical patent/JP2013224953A/ja
Publication of JP2013224953A5 publication Critical patent/JP2013224953A5/ja
Pending legal-status Critical Current

Links

JP2013133614A 2005-03-25 2013-06-26 テロメラーゼ陽性細胞におけるテロメア長の調節および癌治療 Pending JP2013224953A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66510505P 2005-03-25 2005-03-25
US60/665,105 2005-03-25

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2008503271A Division JP2008536822A (ja) 2005-03-25 2006-03-27 テロメラーゼ陽性細胞におけるテロメア長の調節および癌治療

Publications (2)

Publication Number Publication Date
JP2013224953A JP2013224953A (ja) 2013-10-31
JP2013224953A5 true JP2013224953A5 (enExample) 2014-05-22

Family

ID=37053967

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008503271A Pending JP2008536822A (ja) 2005-03-25 2006-03-27 テロメラーゼ陽性細胞におけるテロメア長の調節および癌治療
JP2013133614A Pending JP2013224953A (ja) 2005-03-25 2013-06-26 テロメラーゼ陽性細胞におけるテロメア長の調節および癌治療

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2008503271A Pending JP2008536822A (ja) 2005-03-25 2006-03-27 テロメラーゼ陽性細胞におけるテロメア長の調節および癌治療

Country Status (6)

Country Link
US (5) US7741296B2 (enExample)
EP (1) EP1868615A4 (enExample)
JP (2) JP2008536822A (enExample)
CN (2) CN104997783A (enExample)
CA (1) CA2602562C (enExample)
WO (1) WO2006104975A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050113324A1 (en) * 2003-01-15 2005-05-26 Bondarev Igor E. Modulation of line-1 reverse transcriptase
US8609623B2 (en) * 2005-05-18 2013-12-17 Alt Solutions Inc. Pharmacological modulation of telomere length in cancer cells for prevention and treatment of cancer
EP2001488A4 (en) * 2006-03-14 2009-11-25 Alt Solutions Inc PREVENTION AND TREATMENT OF CANCER AND OTHER DISEASES
EP2794624B1 (en) 2011-12-22 2019-05-15 Geron Corporation Guanine analogs as telomerase substrates and telomere length affectors
CN102660650A (zh) * 2012-05-25 2012-09-12 云南路易斯中药现代化工程技术研究中心 一种实时定量pcr测量样品中染色体端粒平均长度的绝对值的试剂盒及应用
EP2925889B1 (en) * 2012-11-30 2018-09-05 Geron Corporation Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors
US9795242B2 (en) 2013-02-14 2017-10-24 Cirkul, Inc. Additive delivery systems and containers
ES2748334T3 (es) 2014-11-21 2020-03-16 Cirkul Inc Sistemas de cartuchos de aditivos ajustables
US10888826B2 (en) 2014-11-21 2021-01-12 Cirkul, Inc. Adjustable additive cartridge systems and methods
EP3753563A1 (en) * 2019-06-20 2020-12-23 Helmholtz-Zentrum für Infektionsforschung GmbH Anti-herpesvirus guanosine analogue for the inhibition of basal autophagy
CN112168829B (zh) * 2020-09-24 2022-02-15 华南理工大学 抗病毒药物在制备治疗骨髓增生异常综合征药物中的应用及制得的骨髓增生异常综合征药物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166140A (en) * 1987-05-05 1992-11-24 City Of Hope Use of certain nucleoside analogs to attenuate cancer cell resistance to DNA damaging chemotherapy
US5585363A (en) * 1987-05-05 1996-12-17 City Of Hope Circumvention of human tumor drug resistance
US5489508A (en) * 1992-05-13 1996-02-06 University Of Texas System Board Of Regents Therapy and diagnosis of conditions related to telomere length and/or telomerase activity
US5654286A (en) * 1993-05-12 1997-08-05 Hostetler; Karl Y. Nucleotides for topical treatment of psoriasis, and methods for using same
US5631236A (en) 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
US5981507A (en) * 1995-12-14 1999-11-09 Advanced Magnetics, Inc. Polymeric carriers linked to nucleotide analogues via a phosphoramide bond
GB9601544D0 (en) * 1996-01-26 1996-03-27 Smithkline Beecham Plc Pharmaceuticals
EP1194168B1 (en) * 1999-06-23 2010-03-31 University Of Vermont And State Agricultural College Methods and products for manipulating uncoupling protein expression
US20050113324A1 (en) * 2003-01-15 2005-05-26 Bondarev Igor E. Modulation of line-1 reverse transcriptase

Similar Documents

Publication Publication Date Title
ES2251168T3 (es) Agente antiviral en combinacion con radioterapia para el tratamiento del cancer.
US20150290235A1 (en) Use of small molecule inhibitors/activators in combination with (deoxy)nucleoside or (deoxy)nucleotide analogs for treatment of cancer and hematological malignancies or viral infections
ES2982897T3 (es) Uso del inhibidor de la telomerasa imetelstat para el tratamiento de trastornos mieloproliferativos y neoplasias mieloproliferativas
EA019869B1 (ru) Низкомолекулярные миристатные ингибиторы тирозинкиназы bcr-abl и способы их применения
HK1200716A1 (zh) 使用胞苷類似物的口服製劑治療癌症的方法
JP2009062383A5 (enExample)
Ray et al. Application of kinase bypass strategies to nucleoside antivirals
BR112015023705A2 (pt) composto da fórmula (ia) ou um sal, hidrato, solvato ou forma cristalina farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto, composto e método para síntese do composto da fórmula (ia)
JP2009530295A5 (enExample)
HUP0401987A2 (hu) A triazolil-imidazopiridin és a triazolilpurin vegyületek adenozin-a2A-receptorligandumként használható származékai és gyógyszerként történő alkalmazásuk
RU2018138976A (ru) Лечение рака головного мозга
JP2014144962A5 (enExample)
CN110769837A (zh) 与五氮杂大环状环配合物的联合癌症免疫疗法
De Clercq The Holý Trinity: the acyclic nucleoside phosphonates
JP2014513705A (ja) 進行性固形腫瘍の治療方法
IL193148A (en) Medicine combined with hepatitis B virus
CA2644297A1 (en) Prevention and treatment of cancer and other diseases
JP2007518815A5 (enExample)
CA2602562C (en) Modulation of telomere length in telomerase positive cells and cancer therapy
CA2868024A1 (en) Methods of treating cancer using aurora kinase inhibitors
CN102905709B (zh) 同时、单独或相继用于治疗和/或预防和/或减轻癌症的egfr抑制剂和抗病毒剂
CN118176201B (zh) L-bhdu的前药和治疗病毒感染的方法
KR20240004543A (ko) 혈액암을 치료하는 방법
De Clercq </i> Obituary<//i> The Elegance of the Acyclic Nucleoside Phosphonates (ANPs), Honorary Tribute to Antonin HolATIN SMALL LETTER Y WITH ACUTE, Who Passed Away on 16 July 2012, at the 10th Anniversary of His Death
EA051236B1 (ru) Пролекарства l-bhdu и способы лечения вирусных инфекций